Q4 2025 ADMA Biologics Inc Earnings Call Transcript

Feb 25, 2026 / 09:30 PM GMT

Release Date Price: $15.68 (+1.03%)

Transcript 10-K8-K

Key Points

Positve

ADMA Biologics Inc (ADMA) reported a total revenue of $510 million for 2025, representing a 20% year-over-year growth.
Adjusted EBITDA increased by 40% year-over-year to $231 million, showcasing strong financial performance.
The company's differentiated specialty immunoglobulin, Incentive, achieved $363 million in net revenue, marking a 51% year-over-year growth.
ADMA Biologics Inc (ADMA) successfully integrated yield-enhanced production into commercial operations, leading to improved gross margins.
The company has strategically repositioned its plasma collection network, securing long-term supply visibility and enhancing capital efficiency.

Negative

The increase in working capital reflects the growth in Incentive and the acceleration in revenue growth, which may pose challenges in managing cash flow.
The company is still in the early stages of penetrating its total addressable market, indicating potential risks in achieving projected growth.
ADMA Biologics Inc (ADMA) faces the challenge of normalizing accounts receivable and day sales outstanding, which could impact cash conversion.
The transition of leadership with the retirement of the CFO may pose risks in maintaining financial continuity and strategic execution.
The company's reliance on third-party plasma supply agreements introduces potential risks in supply chain stability and cost management.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ADMA.OQ - ADMA Biologics Inc
Q4 2025 ADMA Biologics Inc Earnings Call
Feb 25, 2026 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon and welcome to the Adma Biologics full year 2025 financial results and business update conference call on Wednesday, February 25, 2026. At this time, all participants are in a listen-only mode. There will be a question-and-answer session to follow. Please be advised that this call is being recorded at the company's request and will be available on the company's website approximately 2 hours following the end of the call. At this time, I would like to introduce the company. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Welcome everyone, and thank you

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.